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Early in the HIV epidemic, people living with HIV
(PLWH) often struggled to maintain body
weight. Since the 1990s, combination antiretroviral therapy (cART) has transformed the lives of
PLWH, reducing morbidity and increasing life
expectancy. In this time, as obesity rates have
surged in the US, obesity and its associated
comorbidities have become major health issues
in PLWH.1-2 Recently, questions have been raised
about a possible association between modern
antiretrovirals, particularly integrase strand-
transfer inhibitors (INSTI), and weight gain with
various management strategies being proposed.
Bariatric surgery is utilized commonly to manage
obesity, but data remains limited regarding
cART outcomes post-operatively considering
the alteration of gastrointestinal anatomy and
subsequent impact on nutrient and/or medication
absorption.3-6 We evaluated outcomes following
bariatric surgery in a cohort of PLWH at an urban,
Ryan White-funded HIV clinic.

Methods

28 PLWH who underwent bariatric surgery were
identified retrospectively. Patients with at least
12 months of follow-up post-operatively were
included for further analysis. Medical records
were abstracted for demographics, HIV viral load
(VL), CD4, cART, weight, BMI, glomerular filtration
rate (GFR, MDRD), hemoglobin A1c and number
of medications taken for comorbidities (diabetes
[DM], hypertension [HTN], hyperlipidemia) at
baseline and up to 36 months post-surgery.
For missing data, last observation was carried
forward but not beyond the current post-surgery
interval. Reasons for virologic rebound, cART
changes and post-operative complications were
also analyzed.

© 2020 Lehigh Valley Health Network

Conclusions

Results

• 25 of 28 PLWH had at least 12 months of post-operative followup and were analyzed. Two were excluded due to lack of baseline
data and 1 with recent surgery and <12 months follow-up.
• At baseline, patients were mainly female (76%) with mean age
of 46 (24-61) and BMI of 43.7 kg/m2 (32-56) and underwent
sleeve gastrectomy (60%) or Roux-en-Y gastric bypass (40%).
• All but 6 patients were taking INSTI as part of their cART at
baseline, limiting ability for pre/post-operative comparative
analysis between cART regimens.
• Mean BMI decreased 28.6% at 12 months to 31.28 kg/m2
(p<0.001) and was maintained through 36 months (31.97
kg/m2, p<0.001) with the steepest declines occurring in the
first 12 months.
• Seven patients had DM with a mean A1c of 8.2% (6.5-11.4) at
baseline. A1c decreased to 5.9% at 12 months (p=0.009).
• Mean DM medication use per patient declined 80% from 2.14
meds per patient (range 1-4) to 0.43 (range 0-2) at 12 months
(p=0.011) and 91% to 0.20 (range 0-1) at 36 months (p=0.034).
• 18 patients were using a mean of 1.78 antihypertensive
medications at baseline. Use decreased to 0.67 meds at 12
months (p<0.001) and 0.60 meds at 36 months (p<0.001).

• No significant changes were identified in GFR and number of
meds used for hyperlipidemia.
• Nausea and acid reflux were common, mainly in the immediate
post-operative period. Two patients interrupted cART briefly
(<4 weeks duration) due to nausea; both had VL <20 copies/
mL at 36 months. One patient switched to liquid cART between
3 and 12 months due to dysphagia and had VL <20 copies/mL
at 36 months.
• Seven patients experienced temporary virologic rebound (VL>200)
during initial follow-up, 3 due to post-surgery complications
(2 nausea, 1 dysphagia), and 4 due to nonadherence. All
patients resuppressed by the end of follow-up.
• No significant change in CD4 count (cells/mm3) was observed
with the exception of a temporary decline in mean CD4 at
3 months from 721.6 at baseline to 640.7 (p=0.012),
rebounding to baseline levels by 6 months (695.8, p=0.443)
and persisting through 36 months (673.5, p=0.215).
• No deaths, opportunistic or post-operative infections occurred in
this cohort.

Table 1: Impact of Bariatric Surgery on Key Metrics
3
6
12
24
36
Baseline month month month month month
25
25
25
25
23
20
263
220
199
186
185
191
119
100
90
84
84
87
43.68 36.86 33.16 31.28 30.91 31.97
92%
84%
80%
92%
87%
90%
721.64 640.68 695.76 704.21 620.39 621.45

Sample (n)
Weight, mean (kg)
Weight, mean (kg)
BMI, mean (kg/m2)
HIV VL <20 (copies/ml)
CD4, mean (cells/mm3)
GFR, mean
82.33
2
(mL/min/1.73m )
Number of BP Meds, mean 1.78
Patients with Diabetes
Baseline
(N=7)
Hemoglobin A1c (%)
8.19
Number of DM Meds, mean 2.14

In the largest cohort of PLWH presented to
date, we demonstrate that bariatric surgery is
an option for PLWH to reduce body weight
and improve outcomes of obesity-related
comorbidities. Most patients experienced a
significant decrease in medication usage for
type 2 diabetes and hypertension. Post-operative
issues impacting cART adherence can be
managed effectively without compromising
long-term virologic control.

Bariatric surgery is an
option for PLWH to
reduce body weight
and improve outcomes
of obesity-related
comorbidities.

Figure 1: Decrease in Body Weight Following
Bariatric Surgery
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